Abstract-The aim of this work was to investigate whether it is possible to remove arrhythmogenic Ca 2ϩ release from the sarcoplasmic reticulum that occurs in calcium overload without compromising normal systolic release. Exposure of rat ventricular myocytes to isoproterenol (1 mol/L) resulted in an increased amplitude of the systolic 
Abstract-The aim of this work was to investigate whether it is possible to remove arrhythmogenic Ca 2ϩ release from the sarcoplasmic reticulum that occurs in calcium overload without compromising normal systolic release. Exposure of rat ventricular myocytes to isoproterenol (1 mol/L) resulted in an increased amplitude of the systolic Ca 2ϩ transient and the appearance of waves of diastolic Ca 2ϩ release. Application of tetracaine (25 to 50 mol/L) decreased the frequency or abolished the diastolic Ca 2ϩ release. This was accompanied by an increase in the amplitude of the systolic Ca 2ϩ transient. Cellular Ca 2ϩ flux balance was investigated by integrating Ca 2ϩ entry (on the L-type Ca 2ϩ current) and efflux (on Na-Ca 2ϩ exchange). Isoproterenol increased Ca 2ϩ influx but failed to increase Ca 2ϩ efflux during systole (because of the abbreviation of the duration of the Ca 2ϩ transient). To match this increased influx the bulk of Ca 2ϩ efflux occurred via Na-Ca 2ϩ exchange during a diastolic Ca 2ϩ wave. Subsequent application of tetracaine increased systolic Ca 2ϩ efflux and abolished the diastolic efflux. The increase of systolic efflux in tetracaine resulted from both increased amplitude and duration of the systolic Ca 2ϩ transient. In the presence of isoproterenol, those Ca 2ϩ transients preceded by diastolic release were smaller than those where no diastolic release had occurred. When tetracaine was added, the amplitude of the Ca 2ϩ transient was similar to those in isoproterenol with no diastolic release and larger than those preceded by diastolic release. We conclude that tetracaine increases the amplitude of the systolic Ca Key Words: spontaneous release Ⅲ calcium Ⅲ sarcoplasmic reticulum Ⅲ arrhythmias I n cardiac myocytes, an increase of sarcoplasmic reticulum (SR) Ca 2ϩ load increases both systolic Ca 2ϩ release and force of contraction. This occurs largely through the release of Ca 2ϩ ions from the SR via a release channel known as the ryanodine receptor or (RyR) (see Bers 1 for review). However, when too much Ca 2ϩ enters the SR (Ca 2ϩ overload), Ca 2ϩ is also released spontaneously during diastole. [2] [3] [4] This occurs as a result of increased RyR open probability secondary to increased SR Ca 2ϩ content. 5 This diastolic Ca 2ϩ release activates the electrogenic sodium/calcium exchanger (NCX) and produces inward current resulting in delayed afterdepolarizations (DADs). 6 -8 DADs play a role in the genesis of arrhythmias in many clinical settings such as heart failure, 9 digitalis toxicity, catecholaminergic ventricular tachycardia, and reperfusion arrhythmias. 10 In addition, this tendency to diastolic Ca 2ϩ release limits the use of positive inotropes that work by increasing SR Ca 2ϩ content. The aim of the present work was to develop a strategy to abolish the potentially arrhythmogenic diastolic Ca 2ϩ release from the SR. The challenge was to do this without interfering with the normal systolic Ca 2ϩ release. Because both forms of release occur through the RyR, this is not simple. Recent work has demonstrated that JTV519 (an agent that reduces RyR open probability by increasing binding of the accessory protein FKBP12.6 to the RyR) prevents the development of ventricular arrhythmias following ␤-adrenergic stimulation in transgenic mice that have a reduced expression of FKBP12.6. 11 (This agent also protected against heart failure in a canine model 12 ). However, neither of these studies investigated changes of cellular Ca 2ϩ handling. Furthermore, the fact that an agent affecting FKBP12.6 binding to the RyR protects against arrhythmias induced by decreased FKBP12.6 does not provide information about whether maneuvers that affect RyR opening in other ways will also be antiarrhythmic. Previous work has shown that the local anesthetic tetracaine, by reducing RyR P o , decreases the frequency of spontaneous Ca 2ϩ release in unstimulated rat ventricular myocytes 13 and has no effect on the systolic 
Materials and Methods
Experiments were performed on single ventricular myocytes isolated from Wistar rats. Myocytes were isolated by collagenase/protease digestion as described previously. 15 Voltage clamp was imposed using the perforated patch technique with amphotericin-B. Electrodes (1.5 to 3 M⍀ resistance) were back filled with solution containing (in mmol/L) CsCH 3 O 3 S 115, CsCl 20, NaCl 12, HEPES 10, Cs 2 EGTA 0.1, and MgCl 2 5, titrated to pH 7.2 with CSOH. The concentration of amphotericin-B was 240 g/mL. Final access resistance was typically Ϸ20 M⍀ and was overcome using the switch-clamp facility of a Axoclamp-2A amplifier (Axon Instruments, Union City, Calif). Cells were stimulated with 100-ms pulses (from Ϫ40 to 0 mV) at 0. Where applicable, the data are reported as the meanϮSEM of n experiments. Significance was tested using either t test or 1-way ANOVA. It is known that tetracaine can also inhibit the I Ca,L . 14, 18 This raises the question of whether the effects of tetracaine on Ca handling are attributable to a pure inhibition of RyR or to a combined effect of RyR and I Ca,L inhibition. We found that, at a concentration of 50 mol/L, tetracaine had no effect (Pϭ0.24) on the peak amplitude of I Ca,L (1.28ϮϪ0.12 nA in isoproterenol and 1.32Ϯ0.13 nA in isoproterenolϩtetracaine). At a higher concentration of tetracaine (100 mol/L), there was a 9.1Ϯ1.2% decrease in the amplitude of the current, and, therefore, all subsequent analysis is based on the results obtained using 50 mol/L tetracaine in cells that exhibited spontaneous release in isoproterenol.
Results
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Previous work has shown that the Ca 2ϩ released during diastolic waves activates Na-Ca exchange and that the Ca 2ϩ efflux resulting from this is important for cellular Ca 2ϩ balance. 19 The question then arises as to how cellular Ca 2ϩ flux balance is maintained when the efflux produced by diastolic Ca 2ϩ release is removed. The upper traces of Figure  2 show the effects of isoproterenol (b) . This is more problematic in the presence of isoproterenol, where the Ca 2ϩ transient is larger and decays more quickly than under control conditions, ie, more of the transient takes place during the pulse. To address these issues and obtain a more precise measure of Ca 2ϩ influx and efflux during the pulse, we have calculated the Ca 2ϩ efflux on NCX during the depolarizing pulse. 20 In any given cell, we measure the relationship between changes of [Ca 2ϩ ] i and NCX current on repolarization to Ϫ40 mV. In 7 cells, we measured the relationship between [Ca 2ϩ ] i and NCX current in response to caffeine and found that at 0 mV, the slope was 58% of that at Ϫ40 mV. From this ratio and the observed relationship at Ϫ40 mV, we calculated the slope of the relationship at 0 mV and used this to estimate the NCX current during the pulse. This estimation of NCX current was then used to correct both I Ca,L -mediated systolic Ca 2ϩ influx and NCX mediated Ca 2ϩ efflux.
The results obtained from this analysis are summarized in the 
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tetracaine in 9 cells ( Figure 3A) . The rate constant of decay was decreased from 20.2Ϯ1.1 sec Ϫ1 in isoproterenol to 15.5Ϯ1.3 sec Ϫ1 in 50 mol/L tetracaine (Pϭ0.001). Therefore, both the slowing of decay of the transient and the increase in its amplitude contribute to the increased Ca Figure 3B ), 50 mol/L tetracaine had no significant effect and the mean regression coefficient was Ϫ0.127Ϯ0.015 nA/mol per liter in isoproterenol and Ϫ0.141Ϯ0.017 nA/ mol per liter in isoproterenolϩ50 mol/L tetracaine (Pϭ0.111). On the basis of this finding, we can conclude that tetracaine does not change NCX function.
What Causes the Increase of Ca 2؉ Transient Amplitude After Application of Tetracaine?
The finding that an agent such as tetracaine that decreases RyR opening increases the amplitude of the systolic Ca 2ϩ transient is surprising. Previous work found that, in the steady state, tetracaine did not have any effect on either the Ca 2ϩ transient amplitude or contraction. 14 The main difference between our experiments and this previous work is that our cells show diastolic Ca 2ϩ release. Previous work has also shown that the occurrence of diastolic Ca 2ϩ waves depresses the subsequent systolic Ca 2ϩ release. [21] [22] [23] [24] Together with our data, these observations are consistent with the hypothesis that Ca 2ϩ waves decrease the following Ca 2ϩ transient and that tetracaine increases the transient amplitude by removing Ca 2ϩ waves. This hypothesis predicts that tetracaine will have no effect on the amplitude of transients that are not preceded by a Ca 2ϩ wave. Figure 4A and 4B show that, in isoproterenol, waves are not seen in every diastolic period. Ca 2ϩ transients preceded by a wave (a) tend to be smaller than those where the previous diastolic period did not have a wave (b). Figure 4C shows mean data from 5 cells. The mean amplitude of the systolic Ca 2ϩ transients preceded by a wave was 1.08Ϯ0.06 mol/L, and this was less than the value when no diastolic wave occurred ( 
Discussion
Inhibition of RyR achieved using JTV519 has been shown to prevent the onset of ventricular arrhythmias after ␤-adrenergic stimulation. 10 The 2 aims of the present work were (1) to establish whether, at a cellular level, selective RyR inhibition (achieved by using tetracaine) could be used to remove the unwanted diastolic Ca 2ϩ release from the SR and the associated arrhythmogenic inward current and (2) to study the effects of RyR inhibition on the systolic Ca Previous work has investigated the effects of tetracaine under 2 conditions. (1) When applied to Ca 2ϩ -overloaded cells clamped at a constant membrane potential, tetracaine decreased the frequency of spontaneous Ca 2ϩ waves and increased the Ca 2ϩ efflux on each wave. 13 This is explained by tetracaine increasing the threshold SR Ca 2ϩ content at which a wave occurs. As a result, there is an increase in the amount of Ca 2ϩ released and the wave is larger. This, however, results in increased Ca 2ϩ efflux and, therefore, at a constant influx of Ca 2ϩ into the cell, it takes longer for the SR to reaccumulate this calcium and the frequency of Ca 2ϩ release is decreased. (2) When applied to nonoverloaded cells stimulated to produce Ca 2ϩ transients, tetracaine produces a transient decrease in the amplitude of the Ca 2ϩ transient and contraction but, after a few beats, contraction returns to levels similar to control. 14 The transient nature of the response is explained by the fact that the initial decrease in systolic Ca 2ϩ on application of tetracaine decreases the Ca 2ϩ efflux from the cell thereby increasing SR Ca 2ϩ and hence allowing the systolic Ca 2ϩ transient to recover. In the steady state, the Ca 2ϩ efflux from the cell must balance the Ca 2ϩ entry that is largely via the I Ca,L . If this influx is constant, then the efflux must be constant and therefore the amplitude of the Ca 2ϩ transient in tetracaine must be the same as in control. 25 influx in rat ventricular myocytes. 30 The latter possibility is suggested by recent work indicating that during adrenergic stimulation, the calcium current can activate Ca 2ϩ entry on NCX. 31 However, on the basis of this explanation, one would expect the unresolved influx to be greater in isoprenaline than control and this is not the case. 35 The results of this report do not allow us to distinguish among these possibilities.
Tetracaine Increases the
Are the Effects of Tetracaine Exclusively Attributable to Actions on RyR?
Tetracaine has actions at sites other than the RyR. (1) It inhibits the Na current. This is not a problem in the present experiments because of the holding potential used. (2) It can also decrease the I Ca,L . 36 However, on average we found no effect of 50 mol/L tetracaine on the peak calcium current. 28 We conclude that the effects of tetracaine we report are exclusively mediated by RyR inhibition.
What Would Be the Effect of Tetracaine on Entire Heart Contractility?
One important question regarding the use of a RyR inhibitor as an antiarrhythmic concerns its effects on the contraction of the whole heart. Many of the available antiarrhythmic agents have profound negative inotropic effects that make them unsuitable for use in heart failure, among the most common causes of arrhythmias. From our experiments, it is very difficult to reach a conclusion on the overall effect of RyR inhibition on cardiac contractility; however, it is worth considering a few points.
(1) The observation that tetracaine (50 mol/L) has mild negative inotropic effects only in nonoverloaded cells and that, in overloaded cells, tetracaine produces positive inotropic effects suggests that the overall effect will depend on the percentage of cells that are Ca 2ϩ overloaded and that the higher this percentage is, the more likely a positive inotropic effect is. (2) At higher concentrations of tetracaine, and therefore higher levels of RyR inhibition, the negative inotropic effects will become more pronounced. (3) In multicellular preparations, the overall negative inotropic action produced by Ca 2ϩ waves is much bigger than would be expected from the simple summation of the negative inotropic effects in single cells. This is mainly attributable to the fact that the cells are mechanically connected and weakly activated cells are stretched by the fully activated ones and dissipate some of the work produced by the fully activated cells. 2 A maneuver that reduces the number of cells that exhibit waves and are weakly activated will increase force of contraction. One can hypothesize that at relatively low concentrations (50 mol/L), tetracaine could produce a positive inotropic effect (leaving aside the effect on I Na ).
The main conclusion of this report is that selective reduction of the open probability of the RyR abolishes diastolic Ca 2ϩ release, while potentiating systolic release. This may provide the basis of a new antiarrhythmic strategy that could be valuable in many clinical situations. To pursue this strategy further, an agent which selectively and reversibly decreases the open probability of the RyR must be developed.
